Title
Gemfibrozil induces anemia, leukopenia and reduces hematopoietic stem cells via PPAR-α in mice
Date Issued
02 July 2020
Access level
open access
Resource Type
journal article
Author(s)
Estrela G.R.
Arruda A.C.
Torquato H.F.V.
Freitas-Lima L.C.
Perilhão M.S.
Wasinski F.
Budu A.
Fock R.A.
Araujo R.C.
Federal University of São Paulo
Publisher(s)
MDPI AG
Abstract
Hypercholesterolemia, also called high cholesterol, is a form of hyperlipidemia, which may be a consequence of diet, obesity or diabetes. In addition, increased levels of low-density lipoprotein (LDL) and reduced levels of high-density lipoprotein (HDL) cholesterol are associated with a higher risk of atherosclerosis and coronary heart disease. Thus, controlling cholesterol levels is commonly necessary, and fibrates have been used as lipid-lowering drugs. Gemfibrozil is a fibrate that acts via peroxisome proliferator-activated receptor alpha to promote changes in lipid metabolism and decrease serum triglyceride levels. However, anemia and leukopenia are known side effects of gemfibrozil. Considering that gemfibrozil may lead to anemia and that gemfibrozil acts via peroxisome proliferator-activated receptor alpha, we treated wild-type and peroxisome proliferator-activated receptor alpha-knockout mice with gemfibrozil for four consecutive days. Gemfibrozil treatment led to anemia seven days after the first administration of the drug; we found reduced levels of hemoglobin, as well as red blood cells, white blood cells and a reduced percentage of hematocrits. PPAR-alpha-knockout mice were capable of reversing all of those reduced parameters induced by gemfibrozil treatment. Erythropoietin levels were increased in the serum of gemfibrozil-treated animals, and we also observed an increased expression of hypoxia-inducible factor-2 alpha (HIF-2α) and erythropoietin in renal tissue, while PPAR-alpha knockout mice treated with gemfibrozil did not present increased levels of serum erythropoietin or tissue HIF-2α and erythropoietin mRNA levels in the kidneys. We analyzed bone marrow and found that gemfibrozil reduced erythrocytes and hematopoietic stem cells in wild-type mice but not in PPAR-alpha-knockout mice, while increased colony-forming units were observed only in wild-type mice treated with gemfibrozil. Here, we show for the first time that gemfibrozil treatment leads to anemia and leukopenia via peroxisome proliferator-activated receptor alpha in mice.
Start page
1
End page
10
Volume
21
Issue
14
Language
English
OCDE Knowledge area
Bioquímica, Biología molecular
Subjects
Scopus EID
2-s2.0-85088485304
PubMed ID
Source
International Journal of Molecular Sciences
ISSN of the container
16616596
Sponsor(s)
This work was supported by grants from the Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP; grant 2015/20082–7). Acknowledgments: The authors are thankful to Hospital do Rim–Fundação Oswaldo Ramos.
Sources of information:
Directorio de Producción Científica
Scopus